BACKGROUND: Lung-transplant (LT) recipients are at high risk for COVID-19 due to immunosuppression and respiratory tropism of SARS-CoV-2. The information on the effect of COVID-19 mRNA vaccines to elicit immunogenic responses after a two-dose (2D) regimen in LT recipients is sparse. Thus, we assessed the effect of Pfizer-BioNTech and Moderna mRNA vaccines' 2D regimen on anti-spike responses in immunocompromised LT recipients. METHODS: We utilized serum samples from LT recipients vaccinated for SARS-CoV-2 with 2D of either the Pfizer-BioNTech or Moderna vaccines and 2D-vaccinated naïve (non-transplanted and non-exposed to COVID-19) group. Antibody responses were assessed using the FDA-approved SARS-CoV-2 anti-nucleocapsid protein IgG assay (IgGNC), the SARS-CoV-2 anti-spike protein IgM assay (IgMSP), and the SARS-CoV-2 anti-spike protein IgG II assay (IgGSP). CD4+ T-cell activity was assessed as a marker of immune competence using the ImmuKnow® assay. RESULTS: About 25% (18/73) of SARS-CoV-2 uninfected-LT patients generated a positive spike-IgG response following 2D of vaccines, with 36% (9/25) in the Moderna cohort and only 19% (9/48) in the Pfizer cohort. 2D in LT patients elicited a significantly lesser median IgGSP response (1.7 AU/mL, 95% CI: 0.6-7.5 AU/mL) compared to non-transplanted, uninfected naïve subjects (14,209 AU/mL, 95% CI: 11,261-18,836 AU/mL; p < 0.0001). In LT patients, the Moderna-evoked seropositivity trend was higher than Pfizer. CONCLUSION: 2D COVID-19 vaccination elicits a dampened serological response in LT patients. Whether assessing other arms of host immunity combined with a higher vaccine dose can better capture and elicit improved immunogenicity in this immunocompromised population warrants investigation.
BACKGROUND: Lung-transplant (LT) recipients are at high risk for COVID-19 due to immunosuppression and respiratory tropism of SARS-CoV-2. The information on the effect of COVID-19 mRNA vaccines to elicit immunogenic responses after a two-dose (2D) regimen in LT recipients is sparse. Thus, we assessed the effect of Pfizer-BioNTech and Moderna mRNA vaccines' 2D regimen on anti-spike responses in immunocompromised LT recipients. METHODS: We utilized serum samples from LT recipients vaccinated for SARS-CoV-2 with 2D of either the Pfizer-BioNTech or Moderna vaccines and 2D-vaccinated naïve (non-transplanted and non-exposed to COVID-19) group. Antibody responses were assessed using the FDA-approved SARS-CoV-2 anti-nucleocapsid protein IgG assay (IgGNC), the SARS-CoV-2 anti-spike protein IgM assay (IgMSP), and the SARS-CoV-2 anti-spike protein IgG II assay (IgGSP). CD4+ T-cell activity was assessed as a marker of immune competence using the ImmuKnow® assay. RESULTS: About 25% (18/73) of SARS-CoV-2 uninfected-LT patients generated a positive spike-IgG response following 2D of vaccines, with 36% (9/25) in the Moderna cohort and only 19% (9/48) in the Pfizer cohort. 2D in LT patients elicited a significantly lesser median IgGSP response (1.7 AU/mL, 95% CI: 0.6-7.5 AU/mL) compared to non-transplanted, uninfected naïve subjects (14,209 AU/mL, 95% CI: 11,261-18,836 AU/mL; p < 0.0001). In LT patients, the Moderna-evoked seropositivity trend was higher than Pfizer. CONCLUSION: 2D COVID-19 vaccination elicits a dampened serological response in LT patients. Whether assessing other arms of host immunity combined with a higher vaccine dose can better capture and elicit improved immunogenicity in this immunocompromised population warrants investigation.
Authors: Matteo Mombelli; Nils Rettby; Matthieu Perreau; Manuel Pascual; Giuseppe Pantaleo; Oriol Manuel Journal: Vaccine Date: 2018-09-01 Impact factor: 3.641
Authors: Richard J Kowalski; Diane R Post; Roslyn B Mannon; Anthony Sebastian; Harlan I Wright; Gary Sigle; James Burdick; Kareem Abu Elmagd; Adriana Zeevi; Mayra Lopez-Cepero; John A Daller; H Albin Gritsch; Elaine F Reed; Johann Jonsson; Douglas Hawkins; Judith A Britz Journal: Transplantation Date: 2006-09-15 Impact factor: 4.939
Authors: M Quaglia; T Cena; R Fenoglio; C Musetti; D Cagna; E Radin; S Roggero; A Amoroso; C Magnani; P Stratta Journal: Transplant Proc Date: 2014-09 Impact factor: 1.066
Authors: Shahid Husain; Kashif Raza; Joseph M Pilewski; Diana Zaldonis; Maria Crespo; Yoshi Toyoda; Kathleen Shutt; Kathy Spichty; Carolyn Bentlejewski; Diana L Pakstis; Mary Ellen Carey; Kenneth R McCurry; Adriana Zeevi Journal: Transplantation Date: 2009-06-27 Impact factor: 4.939
Authors: Madhusudhanan Narasimhan; Lenin Mahimainathan; Ellen Araj; Andrew E Clark; John Markantonis; Allen Green; Jing Xu; Jeffrey A SoRelle; Charles Alexis; Kimberly Fankhauser; Hiren Parikh; Kathleen Wilkinson; Annika Reczek; Noa Kopplin; Sruthi Yekkaluri; Jyoti Balani; Abey Thomas; Amit G Singal; Ravi Sarode; Alagarraju Muthukumar Journal: J Clin Microbiol Date: 2021-06-18 Impact factor: 5.948
Authors: Lakshmanane Premkumar; Bruno Segovia-Chumbez; Ramesh Jadi; David R Martinez; Rajendra Raut; Alena Markmann; Caleb Cornaby; Luther Bartelt; Susan Weiss; Yara Park; Caitlin E Edwards; Eric Weimer; Erin M Scherer; Nadine Rouphael; Srilatha Edupuganti; Daniela Weiskopf; Longping V Tse; Yixuan J Hou; David Margolis; Alessandro Sette; Matthew H Collins; John Schmitz; Ralph S Baric; Aravinda M de Silva Journal: Sci Immunol Date: 2020-06-11
Authors: Ilona Cieślak; Magdalena Kwapisz; Olga Tronina; Joanna Gotlib; Wojciech Lisik; Dariusz Wasiak; Marta Hreńczuk; Mansur Rahnama; Piotr Małkowski Journal: Ann Transplant Date: 2022-09-16 Impact factor: 1.479
Authors: Rogier As Hoek; Erik Am Verschuuren; Rory D de Vries; Judith M Vonk; Debbie van Baarle; Marieke van der Heiden; Johanna P van Gemert; Edmund J Gore; Hubert Gm Niesters; Michiel Erasmus; Merel E Hellemons; Sandra Mj Scherbeijn; Nynke Wijbenga; Edris A F Mahtab; Corine H GeurtsvanKessel; Coretta Van Leer Buter Journal: J Heart Lung Transplant Date: 2022-03-16 Impact factor: 13.569
Authors: Eusebi Chiner-Vives; Rosa Cordovilla-Pérez; David de la Rosa-Carrillo; Marta García-Clemente; José Luis Izquierdo-Alonso; Remedios Otero-Candelera; Luis Pérez-de Llano; Jacobo Sellares-Torres; José Ignacio de Granda-Orive Journal: Arch Bronconeumol Date: 2022-04-15 Impact factor: 6.333
Authors: Myron J Levin; Andrew Ustianowski; Stéphane De Wit; Odile Launay; Miles Avila; Alison Templeton; Yuan Yuan; Seth Seegobin; Adam Ellery; Dennis J Levinson; Philip Ambery; Rosalinda H Arends; Rohini Beavon; Kanika Dey; Pedro Garbes; Elizabeth J Kelly; Gavin C K W Koh; Karen A Near; Kelly W Padilla; Konstantina Psachoulia; Audrey Sharbaugh; Katie Streicher; Menelas N Pangalos; Mark T Esser Journal: N Engl J Med Date: 2022-04-20 Impact factor: 176.079
Authors: Ainsley Ryan Yan Bin Lee; Shi Yin Wong; Louis Yi Ann Chai; Soo Chin Lee; Matilda Xinwei Lee; Mark Dhinesh Muthiah; Sen Hee Tay; Chong Boon Teo; Benjamin Kye Jyn Tan; Yiong Huak Chan; Raghav Sundar; Yu Yang Soon Journal: BMJ Date: 2022-03-02